Showing 3011-3020 of 5646 results for "".
- Study Shows Efficient AAV Delivery of Large Genes Using ViGeneron's REVeRT Technologyhttps://modernod.com/news/study-shows-efficient-aav-delivery-of-large-genes-using-vigenerons-revert-technology-1/2481913/ViGeneron announced a peer-reviewed publication in
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-
- Sight Sciences Announces New MIGS Data Demonstrating TCOR Using OMNI Surgical System Lowers IOP and Medication Use at 2 Yearshttps://modernod.com/news/sight-sciences-announces-new-migs-data-demonstrating-tcor-using-omni-surgical-system-lowers-iop-and-iop-reducing-medications-at-2-years/2481863/Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (MIGS) technologies, which were recently presented at the 41st Congress of the European Society of Cataract an
- Bausch + Lomb Completes Acquisition of Xiidrahttps://modernod.com/news/bausch-lomb-completes-acquisition-of-xiidra/2481861/Bausch + Lomb announced it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution 5%), a non-steroid eye drop approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. In June, Bausch + Lomb&
- Bausch + Lomb Launches Lumify Eye Illuminations in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-eye-illuminations-in-the-united-states/2481846/Bausch + Lomb announced the US launch of Lumify Eye Illuminations, a new line of hypoallergenic specialty eye care products developed to cleanse, nourish and brighten the sensitive eye area. “Many products contain chemicals or preservatives that can irritate the del
- Bausch + Lomb Launches Dry Eye Drug Miebo in the United Stateshttps://modernod.com/news/bausch-lomb-launches-dry-eye-drug-miebo-in-the-united-states/2481826/Bausch + Lomb announced the US commercial launch of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). In May, Bausch + Lomb and Novaliq received FDA for Miebo as the first and only FDA-approved
- Alcon: Cataract Surgery with AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependencehttps://modernod.com/news/alcon-cataract-surgery-with-acrysof-iq-vivity-iols-demonstrates-sustained-high-patient-satisfaction-and-reduced-spectacle-dependence/2481819/Alcon revealed final data from its Vivity Registry Study, which monitored real-world patient experiences for up to 12 months post-cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL). Data from
- BVI Expands its Presence in Spain and Portugal Acquiring Medical Mixhttps://modernod.com/news/bvi-expands-its-presence-in-spain-and-portugal-acquiring-medical-mix/2481813/BVI announced it has acquired Medical Mix, an ophthalmic medical device supplier in Spain and Portugal. Financial terms of the deal were not disclosed. BVI said its European footprint with direct sales representatives and infrastructure now spans all major western Eu
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Scientists Develop Therapeutic Model for Potentially Treating Incurable Eye Diseaseshttps://modernod.com/news/scientists-develop-therapeutic-model-for-potentially-treating-incurable-eye-diseases/2481794/Researchers have successfully transplanted human microglia cells into mouse retina to create a model that could be used to test new treatments for retinal and central nervous system diseases, according to not-for-profit eLife. Microglia are the innate immune cells of the cent